Nanomedicine News RSS Feed - Nanomedicine

Tekmira Licenses Lipid Nanoparticle Technology for Dicerna's PH1 Development Program

Tekmira Licenses Lipid Nanoparticle Technology for Dicerna's PH1 Development Program

Tekmira Pharmaceuticals Corporation a leading developer of RNA interference (RNAi) therapeutics, today announces a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. Tekmira has licensed its proprietary lipid nanoparticle (LNP) delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program. [More]
Stem Cell Therapy and Nanotechnology Drive Global Regenerative Medicine Market

Stem Cell Therapy and Nanotechnology Drive Global Regenerative Medicine Market

Research and Markets has announced the addition of the "Global Regenerative Medicines Market 2014-2020 - Technology, Application and Geography Analysis of the $67 Billion Industry" report to their offering. [More]
Cell Stays Alive with Nanoscale Film Coating

Cell Stays Alive with Nanoscale Film Coating

Some bacteria form endospores on cell walls to protect their DNA in case of nutrient deficiency. When an endospore meets a suitable environment for survival, the cell can revert to the original state from which it can reproduce. [More]
BSI Awards ISO 13485:2003 Certification to Nanomix

BSI Awards ISO 13485:2003 Certification to Nanomix

Nanomix Inc., a leading nanotechnology company focused on the development of mobile diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced it has received International Standards Organization (ISO) 13485:2003 certification. The certification was awarded by the British Standards Institution (BSI), one of the world's leading certification bodies. [More]
New Hybrid Vehicle for Delivery of Genetically Engineered DNA Vaccines

New Hybrid Vehicle for Delivery of Genetically Engineered DNA Vaccines

A new hybrid vehicle is under development.
Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. [More]
Magnetic Nanoparticles Coated with Targeting Proteins Can Stimulate Stem Cells to Regenerate Bone

Magnetic Nanoparticles Coated with Targeting Proteins Can Stimulate Stem Cells to Regenerate Bone

Researchers in bone tissue regeneration believe they have made a significant breakthrough for sufferers of bone trauma, disease or defects such as osteoporosis. [More]
Iron-Oxide Based Nanoparticles Destroy Cancer Cells Using Photo-Thermal Therapy

Iron-Oxide Based Nanoparticles Destroy Cancer Cells Using Photo-Thermal Therapy

Conventional treatment seeks to eradicate cancer cells by drugs and therapy delivered from outside the cell, which may also affect (and potentially harm) nearby normal cells. [More]
New Multiple Drug Eluting Vaginal Ring from Particle Sciences

New Multiple Drug Eluting Vaginal Ring from Particle Sciences

Particle Sciences, Inc (PSI), the leading CDMO for drug eluting devices, has developed and manufactured a new innovative vaginal ring for Ladee Pharma Research Institute (LPRI), the Research and Development arm of Exeltis Pharmaceuticals. [More]
Merrimack Presents Phase 1 Results from Ferumoxytol Iron Oxide Nanoparticle Study at 26th EORTC-NCI-AACR Symposium

Merrimack Presents Phase 1 Results from Ferumoxytol Iron Oxide Nanoparticle Study at 26th EORTC-NCI-AACR Symposium

Merrimack Pharmaceuticals, Inc. today announced data from multiple presentations at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics. Data presented includes the first public presentation on the preclinical activity and potency of MM-131, and preclinical and clinical data on MM-151. [More]
Novavax' Nanoparticle Vaccine for Infant Protection via Maternal Immunization Granted FDA Fast Track Designation

Novavax' Nanoparticle Vaccine for Infant Protection via Maternal Immunization Granted FDA Fast Track Designation

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F vaccine) for protection of infants via maternal immunization. [More]